Excellent After Sale Service
Excellent Product! Felt the beneficial effects 3 weeks after starting it. Also Excellent After Sale Service. Experienced some issues when ordering product but was swiftly resolved with minimal fuss!
Lactobacillus acidophilus NCK2025™ — precision-engineered, LTA-free
What's in the carton
Standard probiotics were designed for general wellness. CodonRX® was designed specifically for people with IBS and underlying gut sensitivity.
Standard probiotics carry LTA — a surface molecule shown to compound existing gut inflammation.1 NCK2025™ is precision-engineered without LTA.
Multi-strain probiotics introduce more LTA, compounding existing inflammation. CodonRX® is a single, high-performance product shown to rebalance gut inflammation.2
CodonRX® is the product of decades of research at North Carolina State University, published in peer-reviewed journals, and protected by two U.S. patents.
NCK2025™ delivers all the colonization benefit of standard L. acidophilus — minus the LTA molecule that signals inflammation. You get gut support without the gut stress.
One strain, rigorously studied, precisely dosed at 20 billion CFU. No guesswork, no filler. Just the strain with 40+ years of documented research behind it.
Daily use helps restore a balanced microbiome — supporting regularity, reducing bloating, and building long-term digestive resilience over 30–60 days of consistent use.
Most probiotic bottles expose contents to air and humidity every time you open them. CodonRX® is individually sealed to protect each capsule from humidity, oxygen, and environmental contaminants.
CodonRX® is the only patented, LTA-free strain probiotic on the market. It delivers all the benefits of a premium probiotic — without the pro-inflammatory trigger that standard strains carry on their surface.
Protected by: U.S. Patents 9,340,792 & 9,980,992
| Serving Size: 2 Capsules | Amount Per Serving |
|---|---|
| L. acidophilus NCK2025™ | 20 Billion CFU* |
Published research shows NCK2025™ significantly reduces pro-inflammatory signals in the gut while boosting anti-inflammatory ones — shifting an over-reactive gut to homeostasis.
This is mechanism-driven, peer-reviewed evidence.
1 Zadeh M, et al. "Induction of intestinal pro- and anti-inflammatory immune responses by lipoteichoic acid-deficient Lactobacillus acidophilus." Journal of Inflammation. 2012;9:4.
2 Mohamadzadeh M, et al. "Regulation of induced colitis by Lactobacillus acidophilus deficient in lipoteichoic acid." Proc. National Academy of Sciences. 2011;108 Suppl 1:4550–4557.
CodonRX® is built on four decades of probiotic research at NC State University and backed by leaders in gastroenterology and nutritional science.
Our labs at NC State spent years researching and developing the anti-inflammatory properties of CodonRX. It's rare for patented research to evolve into a real-world product that enhances quality of life. I'm thrilled to see CodonRX reach the market and hopeful that it will make a meaningful difference in consumer's health.
As a long-time practicing gastroenterologist, I am excited to see the availability of novel products, such as CodonRX®, with its unique probiotic properties.
Protected by two U.S. patents — 9,340,792 & 9,980,992 · Licensed from NC State University
We'll be straight with you: the microbiome doesn't transform overnight. Here's a realistic timeline based on what our customers actually experience.
Some customers notice initial improvements in comfort and regularity within the first two weeks. A brief adjustment period — mild gas or bloating — is normal and typically resolves within the first few days.
"Felt the beneficial effects 3 weeks after starting." This is when most customers report a meaningful change in bloating, gas, and digestive consistency. The NCK2025™ strain is establishing itself.
"Rarely experienced that discomfort at all." At 60 days of daily use, customers report lasting microbiome balance — the kind of change that doesn't disappear when you skip a day.
Patented NCK2025™ — the only LTA-free probiotic. Backed by 40+ years of university research.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. NCK2025™ and CodonRX® are trademarks of CodonRX. U.S. Patents 9,340,792 & 9,980,992. Licensed from NC State University. Individual results may vary.
Common questions about your order, subscription, and what to expect.